Lenz Therapeutics highlights July momentum driven by telehealth expansion and national TV campaigns amid steady adoption.
LENZ Therapeutics (LENZ) reported a 45% month-over-month increase in prescriptions during Q2 2026, citing telehealth initiatives and a national TV push as key drivers. Management described the quarter as one of “continued, though modest, growth” as the company progresses through its launch phase.
The company’s adoption trends have become clearer after several quarters of commercialization, with July showing particular strength. Prior periods had indicated gradual uptake, but the latest figures suggest accelerating demand.
No immediate market reaction was detailed in the earnings call insights.